Seizure Disorders

What it is

Seizure disorders comprise a broader category than epilepsy alone, encompassing conditions that produce seizures (episodes of abnormal electrical activity in the brain) including post-traumatic seizures, febrile seizures (in children), seizures associated with brain tumors or strokes, and the various epilepsy syndromes themselves.

Approximately one-third of patients with seizure disorders are refractory to two or more first-line anti-seizure medications, defining treatment-resistant disease.

Cannabis and cannabis-derived therapies

The 2017 NASEM consensus report identified conclusive or substantial evidence that cannabidiol is effective for treating certain epilepsy syndromes. The evidence base centers on randomized controlled trials in Dravet syndrome and Lennox-Gastaut syndrome, plus subsequent approval for tuberous sclerosis complex.

Epidiolex (the purified plant-derived cannabidiol oral solution) is FDA-approved as a Schedule V prescription medication for these indications, distinct from state medical-cannabis programs. Outside of those three specific syndromes, evidence for cannabis or cannabinoids in seizure control remains less robust.

"Seizure disorders" is a qualifying-condition basis under most US medical cannabis programs, typically as a broader category that includes formally diagnosed epilepsy plus other seizure-causing conditions.

Causes and classifications

Seizures arise from synchronous abnormal electrical discharge in cerebral neurons. Causes include:

• Idiopathic / genetic epilepsy syndromes: Dravet syndrome, Lennox-Gastaut syndrome, juvenile myoclonic epilepsy, childhood absence epilepsy.
• Structural lesions: congenital cortical malformations, tuberous sclerosis complex, post-stroke seizures, post-traumatic seizures, brain tumors.
• Metabolic: hypoglycemia, hypocalcemia, hyponatremia, hepatic or renal failure, alcohol or benzodiazepine withdrawal.
• Infectious: meningitis, encephalitis, brain abscess, post-infectious sequelae.
• Autoimmune: anti-NMDA-receptor encephalitis, LGI1 encephalitis, Rasmussen encephalitis.
• Toxic / drug-induced: stimulant overdose, tricyclic toxicity, bupropion at high dose, theophylline toxicity, certain antibiotics (carbapenems, fluoroquinolones).

International League Against Epilepsy classification separates focal-onset seizures (originating in one brain region) from generalized seizures (involving both hemispheres from onset). Anti-seizure medication selection varies by seizure type and syndrome.

Cannabis-derived therapies vs anti-seizure medications

Standard anti-seizure medications (levetiracetam, lamotrigine, valproate, carbamazepine, oxcarbazepine, topiramate, zonisamide, lacosamide, perampanel, brivaracetam, cenobamate, and many others) remain the evidence-based first-line approach for most seizure disorders. Cannabis-derived options have a narrower evidence base.

Epidiolex framework

Epidiolex (CBD oral solution) is FDA-approved for three specific seizure disorders: Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex. For these conditions, Epidiolex is the evidence-based cannabis-derived therapy with standardized dosing (10-20 mg/kg/day), drug-interaction documentation, and insurance coverage. See the mmjnow epilepsy page for clinical-trial detail and adverse-event profile.

Adjunctive cannabis for other seizure disorders

For seizure disorders outside the Epidiolex indications, evidence is more limited. State medical-cannabis programs typically permit enrollment for any seizure-disorder diagnosis, but trial evidence for THC-containing cannabis specifically in adult-onset focal or generalized epilepsy is sparse. Observational data show mixed results:

• Some patients report seizure reduction with adjunctive cannabis or CBD products.
• Some patients experience seizure breakthrough or new-onset seizures with high-THC cannabis use (THC can lower seizure threshold).
• Pediatric patients with non-Dravet, non-LGS treatment-resistant epilepsy have been enrolled in CBD trials with variable results.

Patients should coordinate cannabis use with their epileptologist, monitor seizure frequency carefully, and adjust standard anti-seizure medication doses only under specialist supervision.

Drug interactions

Cannabinoids (particularly CBD) inhibit several CYP450 enzymes responsible for anti-seizure medication metabolism. Documented clinically significant interactions:

• Clobazam: CBD elevates active N-desmethylclobazam levels. Combined use requires monitoring for excessive sedation; clobazam dose reduction is often needed.
• Valproate: combined use elevates liver enzymes more than either alone. Monthly LFT monitoring recommended for the first 6 months of Epidiolex therapy.
• Phenytoin: narrow therapeutic window; cannabis can alter levels.
• Carbamazepine: narrow therapeutic window; cannabis can alter levels.
• Stiripentol, brivaracetam: levels rise with CBD coadministration.
• Warfarin: cannabis elevates INR through CYP2C9 inhibition; closer monitoring needed.

Pediatric considerations

Pediatric seizure disorders are the strongest cannabis-evidence population. Epidiolex is the only FDA-approved cannabinoid for pediatric use in any condition. State medical-cannabis program enrollment for pediatric seizure-disorder patients requires caregiver designation, additional documentation, and (in most states) a second physician's concurring certification.

Families navigating pediatric seizure disorders should distinguish between:

• Evidence-based prescription Epidiolex for Dravet, LGS, or TSC.
• State-program low-THC CBD oil for other pediatric seizure indications (variable evidence).
• Over-the-counter hemp-derived CBD (not recommended as primary therapy; quality and dose-standardization vary widely).

Cannabis-induced seizures and seizure threshold

In rare cases, cannabis use has been associated with new-onset or breakthrough seizures, particularly with:

• High-potency THC concentrates in cannabis-naive users.
• Synthetic cannabinoids (K2, Spice), which have a well-documented seizure-precipitating profile distinct from plant cannabis.
• Acute cannabis withdrawal in heavy daily users.

Patients with known seizure disorders should generally avoid high-THC concentrates and use lower-potency or CBD-dominant preparations where appropriate.

Practical guidance

• Specialist (epileptologist or neurologist) coordination is essential for any patient adding cannabis to an existing anti-seizure regimen.
• Seizure-diary documentation is critical for evaluating cannabis effect.
• Liver-function monitoring is required for Epidiolex (per FDA label) and is prudent for high-dose state-program CBD use as well.
• Driving restrictions for seizure patients vary by state DMV rules and should be discussed with the treatment team.
• Pre-surgical disclosure is important: cannabis can interact with anesthesia.

Related conditions

Epilepsy is the largest subset of seizure disorders and has its own mmjnow page with detailed Epidiolex clinical-trial coverage. Traumatic-brain-injury can produce post-traumatic seizures. Cancer (brain metastases) can produce structural-lesion seizures.